GM Advisory Group LLC Purchases 284 Shares of Eli Lilly and Company (NYSE:LLY)

GM Advisory Group LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 2.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,989 shares of the company’s stock after acquiring an additional 284 shares during the period. GM Advisory Group LLC’s holdings in Eli Lilly and Company were worth $9,736,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Westwood Holdings Group Inc. grew its position in Eli Lilly and Company by 5.4% during the first quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock valued at $2,987,000 after buying an additional 196 shares during the period. Guardian Capital LP increased its stake in shares of Eli Lilly and Company by 3.0% in the 1st quarter. Guardian Capital LP now owns 921 shares of the company’s stock worth $717,000 after purchasing an additional 27 shares in the last quarter. Linscomb Wealth Inc. raised its holdings in Eli Lilly and Company by 0.5% in the 1st quarter. Linscomb Wealth Inc. now owns 3,389 shares of the company’s stock worth $2,637,000 after purchasing an additional 17 shares during the period. Steel Grove Capital Advisors LLC lifted its position in Eli Lilly and Company by 104.9% during the first quarter. Steel Grove Capital Advisors LLC now owns 795 shares of the company’s stock valued at $618,000 after purchasing an additional 407 shares in the last quarter. Finally, Beck Capital Management LLC grew its holdings in Eli Lilly and Company by 1.9% during the first quarter. Beck Capital Management LLC now owns 8,824 shares of the company’s stock valued at $6,865,000 after purchasing an additional 163 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $748.91 on Friday. The company has a fifty day simple moving average of $868.53 and a two-hundred day simple moving average of $869.14. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $710.96 billion, a P/E ratio of 80.96, a price-to-earnings-growth ratio of 2.76 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the business posted $0.10 EPS. The firm’s revenue was up 20.4% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Citigroup lifted their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Barclays dropped their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Finally, Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.